secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001232524-25-000061
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Q2 GAAP net loss $718M; revenue $1.05B up 2%; updates FY25 guidance
------------------------------------------------------------------------

- Q2 total revenues $1.05B, up 2% YoY; GAAP net loss $718.5M vs $168.6M profit in Q2 2024.
- Non-GAAP adjusted net loss $504.8M vs $360.7M income; FY2025 revenue guidance revised to $4.15-$4.30B.
- Xywav revenue +13% to $415.3M; added ~625 net patients in Q2, active patients ~15,225.
- Renee Gala named President and CEO effective Aug 11; Bruce Cozadd becomes Chairman.
- FDA Priority Review for Zepzelca combo in 1L ES-SCLC (PDUFA Oct 7); dordaviprone PDUFA Aug 18.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/0001232524-25-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/jazz-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001232524-25-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer